Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.
Journal: The Journal of clinical endocrinology and metabolism
Published: September 13, 2022
Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate.
Journal: Rheumatology and therapy
Published: August 30, 2022
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies.
Journal: RMD open
Published: November 12, 2021
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy.
Journal: Arthritis research & therapy
Published: March 22, 2021
Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy.
Journal: Diabetes, obesity & metabolism
Published: December 16, 2020
Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry.
Journal: Annals of the rheumatic diseases
Published: August 28, 2020
Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.
Journal: Arthritis research & therapy
Published: November 05, 2019
Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
Journal: Diabetes, obesity & metabolism
Published: October 16, 2018
Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial.
Journal: Clinical research in cardiology : official journal of the German Cardiac Society
Published: June 26, 2018
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
Journal: Diabetes, obesity & metabolism
Published: August 03, 2017
Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study.
Journal: Clinical research in cardiology : official journal of the German Cardiac Society
Published: June 15, 2017
Last Updated: 09/26/2026